ASH 2021 | The expanding therapeutic landscape of R/R multiple myeloma
Tarek H Mouhieddine
• 11 Dec 2021
Tarek H Mouhieddine, MD, Icahn School of Medicine at Mount Sinai, New York, NY, talks on emerging immunotherapeutic options for patients with multiple myeloma who are refractory to immunomodulatory drugs (IMiDs), anti-CD38 monoclonal antibodies and proteasome inhibitors. In particular, chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies are highly promising treatment options for patients with triple-class and penta-refractory multiple myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
